



Esperion Therapeutics, Inc.
A Division of PGRD
3621 S. State St.
695 KMS Place
Ann Arbor, MI 48108
Tel 734.622.7770
Fax 734.622.7666

January 11, 2005

Ms. Patricia J. Pelke
Chief
Materials Licensing Branch
United States Nuclear Regulatory Commission
Region III
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4351

Re: License No. 21-32115-01

Dear Ms. Pelke,

This is to advise you of a possible change of control of our license. In early February 2004, Esperion Therapeutics, Inc. was acquired by Pfizer Inc and now operates as a semi-autonomous division of Pfizer Global Research & Development. We are unclear as to whether this constitutes direct change of control, indirect change of control, or no change of control.

Management-related responsibilities remain with the Esperion Therapeutics Divisional Leadership Team. Esperion's radiation safety program and radiation safety processes remain the same as they were prior to the acquisition.

Please advise us if any further action is required.

Sincerely,


A handwritten signature in black ink that reads "Roger S. Newton". The signature is written in a cursive, flowing style.

Roger S. Newton, Ph.D., FAHA
Senior Vice President and Director

JAN 14 2005

Esperion[®]
THERAPEUTICS
A DIVISION OF
Pfizer Global Research & Development

3621 S. State Street
695 KMS Place
Ann Arbor, MI 48108



Ms. Patricia J. Pelke
Chief - Materials Licensing Branch
U.S. Nuclear Regulatory Commission - Region III
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4351

